SLC5A2 and type 2 diabetes mellitus: Three clinical trials (summarized in brief below) have consistently shown that SGLT-2 inhibition on top of standard-of-care at the time of the studies (RAS inhibition) significantly reduces the risk of progression of CKD and associated CVD in people with T2DM and CKD.